Metraipolis › archive › dc_63e5d5bcd37a
Safety evaluation of afatinib in patients with a history of interstitial lung disease using data from an administrative claims database in Japan — Europe PMC PMID:41843044
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/41843044
- DOI
- 10.1007/s11096-[numero omesso]-2
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-04T08:30:41.576Z
- SHA-256 of the archived text
9e213d29147f7e091d22fed0c96b49ef6690c086c6165cd024736bcced9482f0- Stable URL of this page
https://metraipolis.com/documento/dc_63e5d5bcd37a
How to cite
Safety evaluation of afatinib in patients with a history of interstitial lung disease using data from an administrative claims database in Japan — Europe PMC PMID:41843044 — Europe PMC (en), https://europepmc.org/article/MED/41843044 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_63e5d5bcd37a (Metraipolis archive dc_63e5d5bcd37a, sha256 9e213d29147f7e091d22fed0c96b49ef6690c086c6165cd024736bcced9482f0)
BibTeX
@misc{dc63e5d5bcd37a,
title = {Safety evaluation of afatinib in patients with a history of interstitial lung disease using data from an administrative claims database in Japan — Europe PMC PMID:41843044},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/41843044},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_63e5d5bcd37a; sha256 9e213d29147f7e091d22fed0c96b49ef6690c086c6165cd024736bcced9482f0},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41843044. Agents can read the archived copy with the MCP tool read_document.